acquired hemophagocytic lymphohistiocytosis associated with malignant disease
ORPHA: 158057
Overview
human disease
Available Treatments (0)
No treatments linked yet
Clinical trials or compassionate use may be available — consult a specialist.
Clinical Presentation
Signs and symptoms associated with acquired hemophagocytic lymphohistiocytosis associated with malignant disease, sourced from HPO and Orphanet clinical annotations.
Abnormal circulating interleukin concentrationElevated circulating hepatic transaminase concentrationHematological neoplasmHypofibrinogenemiaIncreased circulating lactate dehydrogenase concentrationHepatic failureHepatosplenomegalyMyelodysplasiaIncreased CSF protein concentrationAcute myeloid leukemiaDisseminated intravascular coagulationAcute lymphoblastic leukemiaMultiple myelomaHodgkin lymphomaT-cell lymphomaB-cell lymphomaCSF pleocytosisPersistent EBV viremiaBurkitt lymphomaHepatocellular carcinomaNephroblastomaSquamous cell carcinomaColon cancerProstate cancerNeoplasm of the lungHemophagocytosisSplenomegalyPancytopeniaFeverImmune dysregulationIncreased circulating ferritin concentrationElevated circulating C-reactive protein concentrationAbnormal renal physiologyReduced total natural killer cell countThrombocytopeniaDecreased total neutrophil countAnemiaHypertriglyceridemiaHyperbilirubinemia
Classification & Codes
Orphanet Code
ORPHA:158057acquired hemophagocytic lymphohistiocytosis associated with malignant disease
| Orphanet | ORPHA:158057 |
| Treatments | 0 drug(s) |
| Symptoms on record | 39 signs |
| Status | published |
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO